Hydrogen-Rich Water and Resting Metabolism in Young Adults (H2REST)

July 24, 2025 updated by: Nikola Todorovic, University of Novi Sad

Effects of Hydrogen-Rich Water on Resting Metabolism in Healthy Young Adults: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial

The H2REST trial is a randomized, double-blind, placebo-controlled crossover study investigating the acute effects of a single dose of hydrogen-rich water (HRW) on resting metabolism in healthy young adults. Participants complete two testing sessions-receiving either HRW or placebo in a randomized order-followed by standardized metabolic testing. Primary outcomes include resting energy expenditure, respiratory exchange ratio, and substrate utilization measured via indirect calorimetry. The study aims to assess whether acute HRW intake can modulate metabolic rate and fuel preference at rest, and to explore inter-individual variability in response.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
24

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Aged 18-35 years
  • BMI between 18.5 and 25.0 kg/m²
  • Apparently healthy, with no history of chronic disease
  • Non-smoker, not currently using nicotine-containing products
  • Able to provide informed consent
  • Willing to refrain from alcohol, caffeine, and strenuous exercise for 24 hours before each study visit
  • Able to comply with study procedures, including fasting and attending all study visits

Exclusion Criteria:

  • Diagnosed metabolic, cardiovascular, respiratory, gastrointestinal, or endocrine disorders
  • Use of dietary supplements or medications affecting metabolism (within the past 2 weeks)
  • Allergy or intolerance to components of the hydrogen or placebo beverages
  • Pregnant or lactating
  • Shift work or irregular sleep schedule
  • Participation in another clinical study within the past 30 days

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: ARM1: 250 ml of Hydrogen Rich Water
Hydrogen-producing tablets: Tablets designed to dissolve in water and release molecular hydrogen gas, creating hydrogen-rich water that can be consumed to potentially provide antioxidant and anti-inflammatory benefits.
Dietary supplement: Molecular Hydrogen
Participants in this arm will consume a single 250 mL dose of hydrogen-rich water containing approximately 1.6-2.0 ppm of dissolved molecular hydrogen (H₂), The HRW will be ingested following an overnight fast, and resting metabolism will be measured approximately 30-60 minutes post-consumption using indirect calorimetry.
Placebo Comparator: ARM 2: 250 ml of Placebo Water (Non-hydrogen-producing tablets)
Non-hydrogen-producing tablets, identical in appearance and taste to the active supplement
Dietary supplement: Placebo Comparator
Non-hydrogen-producing tablets, identical in appearance and taste to the active supplement

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Resting Energy Expenditure (REE)
Time Frame: Participants will attend three study visits, with each intervention separated by a 7-day washout period to minimize carry-over effects. During each visit, measurements will be conducted approximately 30-60 minutes post-intervention.

The measurements will be obtained during each study visit. Since this is an interventional study assessing the acute effects of molecular hydrogen, measurements will be collected three times:

At baseline, without any intervention (pre-familiarization),

After a single dose of molecular hydrogen, and

After placebo administration.

The period between each intervention will be seven days, serving as a washout period to prevent carry-over effects. All participants will be instructed to maintain their regular diet and to avoid alcohol, caffeine-containing beverages, and strenuous physical activity for at least 24 hours prior to each visit.

Measure Type: Continuous (kcal/day)

Method: Indirect calorimetry

Description: To assess the effect of acute ingestion of hydrogen-rich water versus placebo on resting energy expenditure in healthy young adults.
Participants will attend three study visits, with each intervention separated by a 7-day washout period to minimize carry-over effects. During each visit, measurements will be conducted approximately 30-60 minutes post-intervention.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University of Novi Sad

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
September 1, 2025

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 1, 2025

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 1, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
July 17, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 24, 2025

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
August 1, 2025

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
August 1, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 24, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2025

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 50-10-18/2024-3

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings